Trial Outcomes & Findings for Irritable Bowel Syndrome and Control Volunteers: Diet Challenge (NCT NCT03983434)
NCT ID: NCT03983434
Last Updated: 2025-04-30
Results Overview
Stool samples will be collected over 2 days for measurement of fecal bile acids (mcmol/48h) by high performance liquid chromatography-mass spectometry
Recruitment status
TERMINATED
Study phase
NA
Target enrollment
29 participants
Primary outcome timeframe
48 hours
Results posted on
2025-04-30
Participant Flow
Participant milestones
| Measure |
Healthy Volunteers
Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Constipation
Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Diarrhea
Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
|---|---|---|---|
|
Overall Study
STARTED
|
17
|
3
|
9
|
|
Overall Study
COMPLETED
|
16
|
2
|
6
|
|
Overall Study
NOT COMPLETED
|
1
|
1
|
3
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Irritable Bowel Syndrome and Control Volunteers: Diet Challenge
Baseline characteristics by cohort
| Measure |
Healthy Volunteers
n=17 Participants
Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Constipation
n=3 Participants
Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Diarrhea
n=9 Participants
Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Total
n=29 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
16 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
9 Participants
n=206 Participants
|
28 Participants
n=7 Participants
|
|
Age, Categorical
>=65 years
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
|
Age, Continuous
|
36.3 years
STANDARD_DEVIATION 14.9 • n=99 Participants
|
26.4 years
STANDARD_DEVIATION 6 • n=107 Participants
|
36.1 years
STANDARD_DEVIATION 9.5 • n=206 Participants
|
35.2 years
STANDARD_DEVIATION 12.8 • n=7 Participants
|
|
Sex: Female, Male
Female
|
12 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
21 Participants
n=7 Participants
|
|
Sex: Female, Male
Male
|
5 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
8 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
17 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
9 Participants
n=206 Participants
|
29 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Asian
|
9 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
10 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
|
Race (NIH/OMB)
White
|
8 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
8 Participants
n=206 Participants
|
18 Participants
n=7 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
PRIMARY outcome
Timeframe: 48 hoursStool samples will be collected over 2 days for measurement of fecal bile acids (mcmol/48h) by high performance liquid chromatography-mass spectometry
Outcome measures
| Measure |
Healthy Volunteers
n=16 Participants
Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Constipation
n=2 Participants
Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Diarrhea
n=6 Participants
Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
|---|---|---|---|
|
Total Fecal Bile Acids
|
471.5 mcmol/48 hours
Interval 331.5 to 612.5
|
347 mcmol/48 hours
Interval 159.0 to 535.0
|
329.5 mcmol/48 hours
Interval 145.0 to 515.0
|
PRIMARY outcome
Timeframe: 48 hoursPopulation: One subject in the group of Irritable Bowel Syndrome Patients with Constipation had missing data in short chain fatty acids.
Stool samples will be collected for measurement of measurement of short chain fatty acids (mmol/kg) by liquid chromatography-mass spectrometry
Outcome measures
| Measure |
Healthy Volunteers
n=16 Participants
Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Constipation
n=1 Participants
Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Diarrhea
n=6 Participants
Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
|---|---|---|---|
|
Total Fecal Short Chain Fatty Acids
|
359.8 mmol/kg
Interval 233.1 to 473.2
|
157.1 mmol/kg
Interval 157.1 to 157.1
|
276.9 mmol/kg
Interval 168.6 to 408.1
|
PRIMARY outcome
Timeframe: 48 hoursPopulation: One subject in the group of Irritable Bowel Syndrome Patients with Constipation had missing data in short chain fatty acids
Stool samples will be collected for measurement of measurement of short chain fatty acids (mmol/kg) by liquid chromatography-mass spectrometry
Outcome measures
| Measure |
Healthy Volunteers
n=16 Participants
Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Constipation
n=1 Participants
Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Diarrhea
n=6 Participants
Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
|---|---|---|---|
|
Individual Fecal Short Chain Fatty Acids - Acetate
|
255.7 mmol/kg
Interval 147.5 to 300.1
|
113.9 mmol/kg
Interval 113.9 to 113.9
|
202.5 mmol/kg
Interval 121.7 to 266.0
|
PRIMARY outcome
Timeframe: 48 hoursPopulation: One subject in the group of Irritable Bowel Syndrome Patients with Constipation had missing short chain fatty acids
Stool samples will be collected for measurement of measurement of short chain fatty acids (mmol/kg) by liquid chromatography-mass spectrometry
Outcome measures
| Measure |
Healthy Volunteers
n=16 Participants
Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Constipation
n=6 Participants
Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Diarrhea
n=1 Participants
Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
|---|---|---|---|
|
Individual Fecal Short Chain Fatty Acids - Propionate
|
59.7 mmol/kg
Interval 39.8 to 86.0
|
22.8 mmol/kg
Interval 22.8 to 22.8
|
39.1 mmol/kg
Interval 25.3 to 51.1
|
PRIMARY outcome
Timeframe: 48 hoursStool samples will be collected for measurement of measurement of short chain fatty acids (mmol/kg) by liquid chromatography-mass spectrometry
Outcome measures
| Measure |
Healthy Volunteers
n=16 Participants
Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Constipation
n=1 Participants
Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Diarrhea
n=6 Participants
Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
|---|---|---|---|
|
Individual Fecal Short Chain Fatty Acids - Butyrate
|
57.5 mmol/kg
Interval 29.1 to 70.2
|
20.5 mmol/kg
Interval 20.5 to 20.5
|
37.6 mmol/kg
Interval 16.9 to 91.0
|
PRIMARY outcome
Timeframe: 48 hoursPopulation: Microbiome sequencing was completed on all collected specimens.
Stool samples will be be collected from participants for nucleic acid extraction, shotgun sequencing is used to measure microbial communities and profiles of specimens. Shannon index is calculated to measure the diversity of species. The minimum value is 0. There is no upper limit. The higher the Shannon index is, the greater the diversity of species is.
Outcome measures
| Measure |
Healthy Volunteers
n=16 Participants
Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Constipation
Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Diarrhea
n=7 Participants
Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
|---|---|---|---|
|
Fecal Microbial Population
|
3 units on a scale
Interval 2.75 to 3.5
|
—
|
3.6 units on a scale
Interval 3.2 to 3.8
|
PRIMARY outcome
Timeframe: 48 hoursPopulation: Measures of inulin evolved over time and many subjects did not have inulin measured as a fraction.
Fecal inulin content will be measured using short acid hydrolysis and high-performance liquid chromatography
Outcome measures
| Measure |
Healthy Volunteers
n=7 Participants
Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Constipation
Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Diarrhea
n=3 Participants
Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
|---|---|---|---|
|
Fecal Inulin
|
3.6 % of fructose from inulin/total fructose
Interval 0.8 to 5.4
|
—
|
17.1 % of fructose from inulin/total fructose
Interval 7.4 to 25.0
|
SECONDARY outcome
Timeframe: 48 hoursStool samples will be collected over 2 days for measurement of fecal bile acids (mcmol/48h) by high performance liquid chromatography-mass spectrometry. Percent primary bile acids is then calculated as primary bile acids divided by total bile acids multiplied by 100.
Outcome measures
| Measure |
Healthy Volunteers
n=16 Participants
Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Constipation
n=2 Participants
Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Diarrhea
n=6 Participants
Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
|---|---|---|---|
|
Percent Primary Fecal Bile Acids
|
2.7 % of primary/total fecal bile acids
Interval 1.0 to 26.8
|
0.4 % of primary/total fecal bile acids
Interval 0.3 to 0.5
|
2.1 % of primary/total fecal bile acids
Interval 0.6 to 10.3
|
SECONDARY outcome
Timeframe: 4 daysStool characteristics will be measured using a 4 day bowel diary. Stool frequency is the total number of bowel movements in 4 days summarized on the subject level.
Outcome measures
| Measure |
Healthy Volunteers
n=16 Participants
Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Constipation
n=2 Participants
Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Diarrhea
n=6 Participants
Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
|---|---|---|---|
|
Stool Characteristics - Stool Frequency in 4 Days
|
4.5 Number of bowel movements in 4 days
Interval 4.0 to 5.5
|
0.5 Number of bowel movements in 4 days
Interval 0.0 to 1.0
|
5 Number of bowel movements in 4 days
Interval 2.0 to 10.0
|
SECONDARY outcome
Timeframe: 4 daysStool characteristics will be measured using a 4 day bowel diary. Stool form is on a scale from 1 to 7, where 1=hard lumps, 2=lumps sausage,3=cracked sausage, 4=normal, 5=soft lumps, 6=mushy,7=watery, summarized on the level of bowel movements.
Outcome measures
| Measure |
Healthy Volunteers
n=73 Bowel movements
Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Constipation
n=1 Bowel movements
Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Diarrhea
n=33 Bowel movements
Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
|---|---|---|---|
|
Stool Characteristics - Stool Form
|
4 score on a scale
Interval 3.0 to 5.0
|
1 score on a scale
Interval 1.0 to 1.0
|
5 score on a scale
Interval 4.0 to 6.0
|
SECONDARY outcome
Timeframe: 4 daysStool characteristics will be measured using a 4 day bowel diary. Ease of passage is on a scale from 1 to 7, where 1=manual disimpaction, 2=enema needed, 3=straining needed, 4=normal, 5=urgent without pain, 6=urgent with pain, 7=incontinent, also summarized on the level of bowel movements.
Outcome measures
| Measure |
Healthy Volunteers
n=73 Bowel movements
Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Constipation
n=1 Bowel movements
Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Diarrhea
n=33 Bowel movements
Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
|---|---|---|---|
|
Stool Characteristics - Ease of Passage
|
4 score on a scale
Interval 4.0 to 4.0
|
3 score on a scale
Interval 3.0 to 3.0
|
4 score on a scale
Interval 4.0 to 5.0
|
OTHER_PRE_SPECIFIED outcome
Timeframe: 24 hoursOptional 24-hour dietary intake will be submitted using web-based Automated Self-Administered Dietary Assessment Tool developed by the National Cancer Institute (https://epi.grants.cancer.gov/asa24/). Dietary intake within a 24-hour period in 30-90 days after study enrollment were collected.
Outcome measures
| Measure |
Healthy Volunteers
n=12 Participants
Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Constipation
n=2 Participants
Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
Irritable Bowel Syndrome Patients With Diarrhea
n=6 Participants
Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS
Inulin: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
|
|---|---|---|---|
|
Energy
|
1887.6 kcal
Interval 1563.9 to 2507.5
|
2083.8 kcal
Interval 1801.3 to 2366.4
|
2246.4 kcal
Interval 1540.1 to 2509.8
|
Adverse Events
Healthy Volunteers
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Irritable Bowel Syndrome Patients With Constipation
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Irritable Bowel Syndrome Patients With Diarrhea
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place